1 / 6

Martin and Harris Share Price of Unlisted shares | Planify

After reading our Research Report which have all the required financials, You'll get to know about Martin and Harris Share Price of Pre IPO, Unlisted Shares, and Upcoming IPO to stay up to date with all the latest updates and details of Martin and Harris Laboratories Limited company and Martin and Harris Unlisted Shares in the market.<br><br>To know more visit: - https://planify.in/research-report/martin-and-harris-laboratories/<br>

Harpreet1
Download Presentation

Martin and Harris Share Price of Unlisted shares | Planify

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Contact Us Martin andHarrisShare Price ₹1,240.00 PLACE ORDER S Martin and Harris Unlisted Shares Essentials Share Discover and get a complete analysis on Martin & Harris Pre IPO - Management, Business Model, Financials, Growth, Valuations, Funding Rounds, News and get latest updates on Martin and Harris Share Price. ISIN INE03VV01015 Total Share 39,96,040 Face Value ₹10.00 Profit A몭 er Tax ₹69.11 Crores Total Income ₹296.67 Crores EPS ₹172.96 P/E 7.17 P/B 1240.00 Market Capitalisation ₹495.51 Cr Earnings Yield 13.95 % Sector Health Care Sub-sector Pharmaceuticals Category Upcoming IPO Cashflow - Operations ₹10.13 Crores Cashflow - Financing ₹32.87 Crores Martin & Harris Growth Pro Only Compounded Sales Growth 2.34% 29.33% 29.35% 1 Year 2 Year 3 Year

  2. Portfolio Basket Watchlist More Pro Only Compounded Profit Growth -4.60% 1 Year 7.86% 2Year 33.62% 3Year Pro Only Return On Equity 23.63% 1 Year 32.92% 2Year 38.99% 3Year About Martin and Harris Pre IPO Martin & Harris Laboratories Ltd incorporated in 1996 at Gurgaon, Haryana is a part of “ApeejayGroup”, India’s oldest and largest business conglomerates. Martin & Harris Laboratories Ltd is engaged in the manufacturing of Pharmaceutical, medicinal chemical & botanical products. Besides the core business, it has undertaken the management of its funds through investment in di몭 erent avenuesfetching good returns i.e., mutualfunds, equity–quoted & unquoted, etc. The company has its units located at Roorkee and UNA Himachal Pradesh Its authorized share capital is ₹500,000 and its paid-up capital is ₹207,600. Martin & Harris is majorly in the manufacturing (Metals & Chemicals, and products thereof) business for the last 41 years and currently, company operations are active. Martin & Harris Product & Services Pharmaceutical Products Bulk Drugs Medicine (Allopathic) Clopidogrel Nicorandil Losartan Potassium Metoprolol Tartrate Martin & Harris Industry Overview

  3. Industry Statistics In FY2020, the pharmaceutical sales grew 9% y-o-y to ₹10,342 Cr. India contributes the second-largest share of the pharmaceutical and biotech workforce in the world. In FY2020, the pharmaceutical sales grew 9% y-o-y to ₹10,342 Cr. India contributes the second largest share of the pharmaceutical and biotech workforce in the world. Indian pharmaceutical sector supplies over 50% of the global demand for various vaccines, 40% of the generic demand for the US, and 25% of all medicines for the UK. During December 2019, on a moving annual total (MAT) basis, industry growth was at 9.8%, with price growth at 5.3%, new product growth at 2.7%, while volume growth at 2% y-o-y. Medicine spending in India is projected to grow 9-12% over the next five years, leading India to become one of the top 10 countries in terms of medical spending. India's biotechnology industry comprising biopharmaceuticals, bio-services, bio-agriculture, bio- industry, and bioinformatics is expected to grow at an average growth rate of around 30% a y-o-y to reach ₹7,24,800 Cr by 2025. Indian pharmaceutical sector is expected to grow to ₹7,24,800 Cr, while the medical device market is expected to grow by ₹1,81,200 in 2025. Pharmaceuticals exports from India stood at ₹1,500,54 Cr in FY20. Pharmaceutical export includes bulk drugs, intermediates, drug formulations, biologicals, Ayush and herbal products and surgical. Government Initiatives Pharma Vision 2020’ by the Government’s Department of Pharmaceuticals aims to make India a major hub for end-to-end drug discovery. The sector received cumulative Foreign Direct Investment (FDI) worth ₹1,19,898 Cr between April 2000 and June 2020. Under Union budget 2020-21, allocation to the Ministry of Health and Family Welfare stands at ₹65,012 crores, whereas, ₹6,429 crores have been allocated to the health insurance scheme, Ayushman Bharat – Pradhan Mantri Jan Arogya Yojana (ABPMJAY). Martin & Harris Strengths Martin & Harris Shortcomings Martin & Harris enjoys a High EBITDA & PAT The company’s Cash Flow from Operations margin compared to its listed peers. has been decreasing at a CAGR of -208.4 % Martin & Harris also depicts high CAGR from 2017 to 2020. In the year 2020, the company has recorded growth in total income compared to peers negative growth of4.6% in Profit a몭 er tax over the period of 4 years. Debt/ Equity ratio is the lowest and the Asset resulting in ₹69 Cr as against ₹72 Cr in FY20 Turnover ratio is higher compared to peers.

  4. The company’s EBITDA has been increasing at a CAGR of 30.9% from 2017 to 2020. Martin & Harris Laboratories Ltd. has a higher ROCE Ratio. The company’s ROCE Ratio is 34.2% if compared to Industry Average ROCE is 21.4%. The company’s Operating profit has been increasing at a CAGR of 30.2% from 2017 to 2020. Martin & Harris Opportunities Martin & Harris Threats The COVID-19 pandemic had a moderate to Threats include several factors, such as new high impact on the global clinical laboratory generic products that arrive in the market, services market. new regulations, new trade barriers, Increasing cases of COVID-19 infected changes to health insurance regulation, and even the lack of availabilityofqualifiedsta몭. patients across the globe has led to a rise in clinical chemistry services, especially in the specialized chemistry testing segment. Laboratory testing and pharma demands have increased significantly and continue to grow at a staggering rate to keep pace with suspected cases of COVID-19, thus boosting the market revenue. Martin & Harris Rating RECOMMENDATION Strong Buy Martin & Harris Detail Info

  5. Industry Statistics PRIVATE LIMITED Registered In India last Updated 25/03/2021 Registered Date 22/07/1993 Planify Ticker M&H RegO몭ice: NH-8,DelhiJaipur Highway,Village, Pachgaon (Fazalwas),Distt.Gurgaon, Haryana Website: None Licensed By Team About Us Channel Partner Contact Us Careers Sitemap Pre-IPO Planify Consultancy India Pvt. Ltd Planify Capital India Pvt. Ltd SEBI Registration - NSE:AP2815021843(CM Segment), AP2815021843(FO Segment), MCX:AP144517 Mutual Fund License No. ARN-164419 , IRDA Code: ABLIC1003123454, ABLIC1003131639 90b, Delhi - Jaipur Expy, Sector 18,

  6. Gurugram, Haryana 122008, India View larger map Keyboard shortcuts Map data ©2021 Terms of Use Report a map error 91 Springboard, NH8-Udyog Vihar, 90B Sector 18, Gurugram, Haryana 122008 Privacy Policy | Cancellation & Refund | Terms & Conditions Copyright © 2019 Planify.in. All Rights Reserved Powered by Inwoin

More Related